scholarly journals Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes

2021 ◽  
Vol 22 (4) ◽  
pp. 1606
Author(s):  
Ah Ram Lee ◽  
Ju-Yeon Cho ◽  
Jong Chul Kim ◽  
Mehrangiz Dezhbord ◽  
Soo Yeun Choo ◽  
...  

Tenofovir disoproxil fumarate (TDF) has been regarded as the most potent drug for treating patients with chronic hepatitis B (CHB). However recently, viral mutations associated with tenofovir have been reported. Here, we found a CHB patient with suboptimal response after more than 4 years of TDF treatment. Clonal analysis of hepatitis B virus (HBV) isolated from sequential sera of this patient identified the seven previously reported TDF-resistant mutations (CYELMVI). Interestingly, a threonine to alanine mutation at the 301 amino acid position of the reverse-transcriptase (RT) domain, (rtT301A), was commonly accompanied with CYELMVI at a high rate (72.7%). Since the rtT301A mutation has not been reported yet, we investigated the role of this naturally occurring mutation on the viral replication and susceptibility to tenofovir in various liver cells (hepatoma cells as well as primary human hepatocytes). A cell-based phenotypic assay revealed that the rtT301A mutation dramatically impaired the replication ability with meaningful reduction in sensitivity to tenofovir in hepatoma cell lines. However, attenuated viral replication by the rtT301A mutation was significantly restored in primary human hepatocytes (PHHs). Our findings suggest that the replication capability and drug sensitivity of HBV is different between hepatoma cell lines and PHHs. Therefore, our study emphasizes that validation studies should be performed not only in the liver cancer cell lines but also in the PHHs to understand the exact viral fitness under antiviral pressure in patients.

PLoS ONE ◽  
2019 ◽  
Vol 14 (9) ◽  
pp. e0223022
Author(s):  
Francois Helle ◽  
Etienne Brochot ◽  
Carole Fournier ◽  
Véronique Descamps ◽  
Laure Izquierdo ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (8) ◽  
pp. e70809 ◽  
Author(s):  
Francois Helle ◽  
Etienne Brochot ◽  
Carole Fournier ◽  
Véronique Descamps ◽  
Laure Izquierdo ◽  
...  

2010 ◽  
Vol 299 (3) ◽  
pp. G778-G783 ◽  
Author(s):  
Chiara Rapisarda ◽  
Juliana Puppi ◽  
Robin D. Hughes ◽  
Anil Dhawan ◽  
Sebastien Farnaud ◽  
...  

Hepcidin expression in vivo is regulated in proportion to iron status (i.e., increased by iron loading and decreased in iron deficiency). However, in vitro studies with hepatoma cell lines often show an inverse relationship between iron status and hepcidin expression. Here, we investigated possible molecular mechanisms responsible for the differences in iron sensing between hepatoma cell lines and human primary hepatocytes. RNA was collected from primary human hepatocytes, and HepG2 and HuH7 hepatoma cells were treated with either transferrin-bound and non-transferrin-bound iron. Expression of hepcidin, transferrin receptor 2, HFE, and hemojuvelin were quantified by real-time PCR. Hepcidin expression was increased in primary human hepatocytes following 24-h exposure to holoferric transferrin. In contrast, hepcidin mRNA levels in hepatoma cells were decreased by transferrin. Hepcidin expression was positively correlated with transferrin receptor 2 mRNA levels in primary human hepatocytes. Compared with primary hepatocytes, transferrin receptor 2 expression was significantly lower in hepatoma cell lines; furthermore, there was no correlation between transferrin receptor 2 and hepcidin mRNA levels in either HepG2 or HuH7 cells. Taken together our data suggest that transferrin receptor 2 is a likely candidate to explain the differences in iron sensing between hepatoma cell lines and primary human hepatocytes.


2015 ◽  
Vol 22 (2) ◽  
pp. 393-399 ◽  
Author(s):  
Di-Yi Wang ◽  
Li-Ping Zou ◽  
Xiao-Jia Liu ◽  
Hong-Guang Zhu ◽  
Rong Zhu

2002 ◽  
Vol 76 (2) ◽  
pp. 912-917 ◽  
Author(s):  
Vicky M.-H. Sung ◽  
Michael M. C. Lai

ABSTRACT We have developed a system for producing murine leukemia virus (MLV) pseudotyped with human hepatitis B virus (HBV) large (L) and small (S) surface antigens (HBsAg) for targeting primary human hepatocytes. Using the MLV(HBV) pseudotype virus containing a β-galactosidase reporter gene, we demonstrated that this pseudotype virus exhibits strict tropism for primary human hepatocytes, similar to the natural target cell specificity of HBV. It does not infect any of the established tissue culture cell lines, including human hepatoma cell lines (HepG2 and Huh-7), or rat primary hepatocytes. The infectivity of MLV(HBV) for human hepatocytes was inhibited by anti-HBs antibody. The L form of HBsAg was both necessary and sufficient for virus infectivity, but the presence of both L and S forms enhanced the surface expression of HBsAg and thus increased virus production. The middle form of HBsAg was not necessary. This pseudotype virus bypasses the requirement for the liver-specific transcription factors for HBV replication, enabling direct study of HBV tissue tropism conferred by the viral envelope proteins. This virus also offers a potential liver-specific targeting system for gene therapy.


2010 ◽  
Vol 23 (5) ◽  
pp. 467-476 ◽  
Author(s):  
Shuang Wu ◽  
Tatsuo Kanda ◽  
Fumio Imazeki ◽  
Makoto Arai ◽  
Yutaka Yonemitsu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document